• 1
    Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P: Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010; 12:R31.
  • 2
    Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143147.
  • 3
    Jorgensen C, Djouad F, Apparailly F, Noel D: Engineering mesenchymal stem cells for immunotherapy. Gene Ther 2003; 10:928931.
  • 4
    Jorgensen C, Djouad F, Fritz V, Apparailly F, Plence P, Noel D: Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine 2003; 70:483485.
  • 5
    Kassis I, Zangi L, Rivkin R, Levdansky L, Samuel S, Marx G, Gorodetsky R: Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplant 2006; 37:967976.
  • 6
    Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H: Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2008; 14:10311038.
  • 7
    Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412415.
  • 8
    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:15791586.
  • 9
    Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez Montes JA: A phase I clinical trials of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48:14161423.
  • 10
    Carrion F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, Mönckeberg G, Figueroa FE: Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010; 19:317322.
  • 11
    Christopeit M, Schendel M, Foll J, Muller LP, Keysser G, Behre G: Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008; 22:10621064.
  • 12
    Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110:34993506.
  • 13
    Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K: Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109:228234.
  • 14
    Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, Anegon I, Cuturi MC: A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110:36913694.
  • 15
    Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F: HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009; 87: 9:S626.
  • 16
    Michelle RB, Asner B, Stella MV, Anthony GM, Mohinder B, Xiao YH, Hong PZ, Melissa D, Stephen M, Kimberley P, Bradley Richard JCN, Douglas WF, Suzanne BP, Joan MR, Samuel NB: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-b superfamily. Proc Natl Acad Sci USA 1997; 94:1151411519.
  • 17
    Bottner M, Laaff M, Schechinger B, Rappold G, Unsicker K, Sutter-Crazzolara C: Characterization of the rat, mouse, and human genes of growth differentiating factor-15/macrophage inhibiting cytokine-1 (GDNF-15/MIC- 1). Gene 1999; 237:105111.
  • 18
    Bottner M, Sutter-Crazzolara C, Scober A, Unsicker K: Expression of a novel member of the TGF-beta superfamily, growth differentiating factor-15/ macriophage inhibiting cytokine-1 (GDNF-15/MIC-1) in adult rat tissues. Cell Tissue Res 1999; 297:103110.
  • 19
    Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier MLC, Russell PK, Salamonsen LA, Wallace EM, Breit SN: The Transforming Growth Factor-β Superfamily Cytokine Macrophage Inhibitory Cytokine-1 Is Present in High Concentrations in the Serum of Pregnant Women. J Clin Endocrinol Metab 2000; 85:47814788.
  • 20
    Bogdan C, Nathan C: Modulation of macrophage function by transforming growth factor beta, IL-4 and IL-10. Ann NY Acad Sci 1993; 685:713739.
  • 21
    Petraglia F, Sacerdote P, Cossarizani A, Angino S, Genazzani AD, Franceschi C, Muscettola M, Grasso G: Inhibin and activin modulate human monocyte chemotaxis and human lymphocyte interferon-gamma production. J Clin Endocrinol Metab 1991; 72:496502.
  • 22
    Tan M, Wang Y, Guan K, Sun Y: PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. PNAS 2000; 97:109114.
  • 23
    Salazar-Onfray F, López MN, Mendoza-Naranjo A: Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18:171182.
  • 24
    Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R: Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180:23712376.
  • 25
    Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R: Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998; 161:20992105.
  • 26
    Moore KW, De Waal Malefyt R, Cffman RL, O’Garra A: Interleukin-10 and interleukin-10 receptor. Annu Rev Immunol 2001; 19:683765.
  • 27
    Serrano AE, Menares-Castillo E, Garrido-Tapia M, Ribeiro CH, Hernández CJ, Mendoza-Naranjo A, Gatica-Andrades M, Valenzuela-Diaz R, Zúñiga R, López MN, Salazar-Onfray F, Aguillón JC, Molina MC: Interleukin 10 decreases MICA expression on melanoma cell surface. Immunol Cell Biol 2011; 89:447457.
  • 28
    Alter G, Malenfant JM, Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 12:1522.
  • 29
    Needleman P, Turk J, Jakschik B, Morrison A, Lefkowith J: Arachidonic acid metabolism. Annu Rev Biochem 1986; 55:69102.
  • 30
    Smith W: Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263:F181F191.
  • 31
    Tilley SL, Coffman TM, Koller BH: Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108:1523.
  • 32
    Goodwin J, Bankhurst A, Messner R: Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med 1977; 146:17191734.
  • 33
    Minakuchi R, Wacholtz M, Davis L, Lipsky P: Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol 1990; 145:26162625.
  • 34
    Scales W, Chensue S, Otterness I, Kunkel S: Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta m-RNA and cell associated bioactivity. J Leukoc Biol 1989; 45:416421.
  • 35
    Van der Pouw Kraan T, Boeije L, Smeenk R, Wijdenes J, Aarden L: Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181:775779.
  • 36
    Snyder D, Beller D, Unanue E: Prostaglandins modulate macrophage Ia expression. Nature 1982; 299:163166.
  • 37
    Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, Kusmartes S: Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009; 182:75487557.
  • 38
    Goetzl E, An S, Smith W: Diversity and specificity of the eicosanoid mediators of normal physiology and disease. FASEB J 1995; 9:10511058.
  • 39
    Betz M, Fox B: Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146:108113.
  • 40
    Katamura K, Shintaku N, Yamauchi Y, Fukui T, Ohshima Y, Mayumi M, Furusho K: Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J Immunol 1995; 155:46044612.
  • 41
    Roper R, Brown D, Phipps R: Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J Immunol 1995; 154:162170.
  • 42
    Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79:11931225.
  • 43
    Sugimoto Y, Narumiya S, Ichikawa A: Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000; 39:289314.
  • 44
    Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762774.
  • 45
    Sono M, Roach M, Coulter E, Dawson J: Heme-containing oxygenases. Chem Rev 1996; 96:28412888.
  • 46
    Shimizu T, Nomiyama S, Hirata F, Hayaishi O: Indoleamine 2, 3-dioxygenase. Purification and some properties. J Biol Chem 1978; 253:47004706.
  • 47
    Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y: Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006; 103:26112616.
  • 48
    Vottero E, Mitchell DA, Page MJ, MacGillivray RTA, Sadowski IJ, Roberge M, Mauk AG: Cytochrome b5 is a major reductant in vivo of human indoleamine 2,3-dioxygenase expressed in yeast. FEBS Lett 2006; 580:22652268.
  • 49
    Maghzal GJ, Thomas SR, Hunt NH, Stocker R: Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. J Biol Chem 2008; 283:1201412025.
  • 50
    Mellor AL, Munn DH: Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20:469473.
  • 51
    Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH: Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002; 168:37713776.
  • 52
    Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB: Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196:459468.
  • 53
    Daubener W, MacKenzie CR: IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol 1999; 467:517524.
  • 54
    Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:12691274.
  • 55
    Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, Durelli I, Horenstein AL, Fiore F, Massaia M, Piccioli M, Pileri SA, Zavatto E, D’Addio A, Baccarani M, Lemoli RM: Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007; 21:353355.
  • 56
    Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A: Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFN. Mol Cancer Ther 2008; 7:38593866.
  • 57
    Holt P, Oliver J, Bilyk N, McMenamin C, McMenamin P, Kraal G, Thepen T: Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993; 177:396407.
  • 58
    Paolucci C, Rovere P, De Nadai C, Manfredi AA, Clementi E: Nitric oxide inhibits the tumor necrosis factor alpha-regulated endocytosis of human dendritic cells in a cyclic GMP-dependent way. J Biol Chem 2000; 275:1963819644.
  • 59
    Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of Dendritic cells. Annu Rev Immunol 2000; 18:767811.
  • 60
    Dinakar C, Malur A, Raychaudhuri B, Buhrow LT, Melton AL, Kavuru MS, Thomassen MJ: Differential regulation of human blood monocyte and alveolar macrophage inflammatory cytokine production by nitric oxide. Ann Allergy Asthma Immunol 1999; 82:217222.
  • 61
    Kallmann BA, Malzkorn R, Kolb H: Exogenous nitric oxide modulates cytokine production in human leukocytes. Life Sci 1999; 65:17871794.
  • 62
    Chang RH, Feng MH, Liu WH, Lai MZ: Nitric oxide increased interleukin-4 expression in T lymphocytes. Immunology 1997; 90:364369.
  • 63
    Bauer H, Jung T, Tsikas D, Stichtenoth DO, Frolich JC, Neumann C: Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2- associated cytokines in activated human T cells. Immunology 1997; 90:205211.
  • 64
    Bingisser RM, Tilbrook PA, Holt PG, Kees UR: Macrophagederived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998; 160:57295734.
  • 65
    Egermann U, Bingisser R: Involvement of an unknown phosphatase in the downregulation of Th1 and Th2-cell proliferation by nitric oxide (NO). Eur J Respir Dis 2000; 16:5s.
  • 66
    Maines MD: Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1998; 2:25572568.
  • 67
    Maines MD, Trakshel GM, Kutty RK: Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J Biol Chem 1986; 261:411419.
  • 68
    McCoubrey Jr WK, Huang TJ, Maines MD: Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 1997; 247:725732.
  • 69
    Yoshida T, Biro P, Cohen T, Muller RM, Shibahara S: Human heme oxygenase cDNA and induction of its mRNA by hemin. Eur J Biochem 1988; 171:457461.
  • 70
    Keyse SM, Tyrrell RM: Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 1989; 86:99103.
  • 71
    Tyrrell RM, Applegate LA, Tromvoukis Y: The proximal promoter region of the human heme oxygenase gene contains elements involved in stimulation of transcriptional activity by a variety of agents including oxidants. Carcinogenesis 1993; 14:761765.
  • 72
    Janssen YM, Marsh JP, Absher MP, Gabrielson E, Borm PJ, Driscoll K, Mossman BT: Oxidant stress responses in human pleural mesothelial cells exposed to asbestos. Am J Respir Crit Care Med 1994; 149:795802.
  • 73
    Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, Green CJ: Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols. J Biol Chem 2000; 275:1361313620.
  • 74
    Cantoni L, Rossi C, Rizzardini M, Gadina M, Ghezzi P: Interleukin-1 and tumor necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids. Biochem J 1991; 279:891894.
  • 75
    Ishikawa K, Navab M, Leitinger N: Induction of heme oxygenase-1 inhibits monocyte transmigration induced by mildly oxidized LDL. J Clin Invest 1997; 100:12091216.
  • 76
    Camhi SL, Alam J, Otterbein L, Sylvester SL, Choi SM: Induction of heme oxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1 activation. Am J Respir Cell Mol Biol 1995; 13:387398.
  • 77
    Koizumi T, Negishi M, Ichikawa A: Induction of heme oxygenase by Δ12-prostaglandin J2 in porcine aortic endothelial cells. Prostaglandins 1992; 43:121131.
  • 78
    Gong P, Stewart D, Hu B, Li N, Cook J, Nel A, Alam J: Activation of the mouse heme oxygenase-1 gene by 15-deoxy-Δ(12,14)-prostaglandin J(2) is mediated by the stress response elements and transcription factor Nrf2. Antioxid Redox Signal 2002; 4:249257.
  • 79
    Hong HY, Jeon WK, Kim BC: Up-regulation of heme oxygenase-1 expression through the Rac1/NADPH oxidase/ROS/p38 signaling cascade mediates the anti-inflammatory effect of 15-deoxy-12,14- prostaglandin J2 in murine macrophages. FEBS Lett 2008; 582:861868.
  • 80
    Negishi M, Odani N, Koizumi T, Takahashi S, Ichikawa A: Involvement of protein kinase in Δ 12-prostaglandin J2-induced expression of rat heme oxygenase-1 gene. FEBS Lett 1995; 372:279282.
  • 81
    Kitamura Y, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T: Activators of peroxisome proliferator-activated receptor-γ (PPARγ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett 1999; 262:129132.
  • 82
    Koizumi T, Odani N, Okuyama T, Ichikawa A, Negishi M: Identification of a cis-regulatory element for Δ 12-prostaglandin J2-induced expression of the rat heme oxygenase gene. J Biol Chem 1995; 270:2177921784.
  • 83
    Jozkowicz A, Huk I, Nigisch A, Weigel G, Weidinger F, Dulak J: Effect of prostaglandin-J(2) on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxid Redox Signal 2002; 4:577585.
  • 84
    Alvarez-Maqueda M, El Bekay R, Alba G, Monteseirĺn J, Chacón P, Vega A, Martın-Nieto J, Bedoya FJ, Pintado E, Sobrino F: 15-Deoxy-Δ 12,14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes. J Biol Chem 2004; 279:2192921937.
  • 85
    Liu JD, Tsai SH, Lin SY, Ho YS, Hung LF, Pan S, Ho FM, Lin CM, Liang YC: Thiol antioxidant and thiol-reducing agents attenuate 15-deoxy-Δ 12,14-prostaglandin J2-induced heme oxygenase-1 expression. Life Sci 2004; 74:24512463.
  • 86
    Kim DH, Kim JH, Kim EH, Na HK, Cha YN, Chung JH, Surh YJ: 15-Deoxy-Δ 12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. Carcinogenesis 2009; 30:645654.
  • 87
    O’Brien JJ, Baglole CJ, Garcia-Bates TM, Blumberg N, Francis CW, Phipps RP: 15-Deoxy-Δ12,14-prostaglandin J2 -induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis. J Thromb Haemost 2009; 7:182189.
  • 88
    Tullius SG, Nieminen-Kelha M, Buelow R, Reutzel-Selke A, Martins PN, Pratschke J, Bachmann U, Lehmann M, Southard D, Iyer S, Schmidbauer G, Sawitzki B, Reinke P, Neuhaus P, Volk HD: Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt protoporphyrin for the induction of heme oxygenase-1. Transplantation 2002; 74:591598.
  • 89
    Shimizu H, Takahashi T, Suzuki T, Yamasaki A, Fujiwara T, Odaka Y, Hirakawa M, Fujita H, Akagi R: Protective effect of heme oxygenase induction in ischemic acute renal failure. Crit Care Med 2000; 28:809817.
  • 90
    Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, Grey ST, Colvin RB, Choi AM, Poss KD, Bach FH: Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 1998; 4:10731077.
  • 91
    Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, Zhao D, Zaky J, Melinek J, Lassman CR, Kolls JK, Alam J, Ritter T, Volk HD, Farmer DG, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW: Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest 1999; 104:16311639.
  • 92
    Sass G, Soares MC, Yamashita K, Seyfried S, Zimmermann WH, Eschenhagen T, Kaczmarek E, Ritter T, Volk HD, Tiegs G: Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice. Hepatology 2003; 38:909918.
  • 93
    Otterbein LE, Kolls JK, Mantell LL, Cook JL, Alam J, Choi AM: Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Invest 1999; 103:10471054.
  • 94
    Petrache I, Otterbein LE, Alam J, Wiegand GW, Choi AM: Heme oxygenase-1 inhibits TNF-α induced apoptosis in cultured fibroblasts. Am J Physiol Lung Cell Mol Physiol 2000; 278:L312L319.
  • 95
    Tamion F, Richard V, Renet S, Thuillez C: Protective effects of heme-oxygenase expression against endotoxic shock: inhibition of tumor necrosis factor-alpha and augmentation of interleukin-10. J Trauma 2006; 61:10781084.
  • 96
    Woo J, Iyer S, Mori N, Buelow R: Alleviation of graft-versus- host disease after conditioning with cobalt-protoporphyrin, an inducer of heme oxygenase-1. Transplantation 2000; 69:623633.
  • 97
    Woo J, Iyer S, Cornejo MC, Mori N, Gao L, Sipos I, Maines M, Buelow R: Stress protein-induced immunosuppression: inhibition of cellular immune effector functions following overexpression of haem oxygenase (Hsp 32). Transpl Immunol 1998; 6:8493.
  • 98
    Pae HO, Oh GS, Choi BM, Chae SC, Chung HT: Differential expressions of heme oxygenase-1 gene in CD25- and CD25+ subsets of human CD4+T cells. Biochem Biophys Res Commun 2003; 306:701705.
  • 99
    Choi BM, Pae HO, Jeong YR, Kim YM, Chung HT: Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun 2005; 327:10661071.
  • 100
    Birchmeier C, Birchmeier W, Gherardi E, Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915925.
  • 101
    Matsumoto K, Nakamura T: Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996; 119:591600.
  • 102
    Rosen EM, Lamszus K, Laterra J, Polverini PJ, Rubin JS, Goldberg ID: HGF/SF in angiogenesis. Ciba Found Symp 1997; 212:215226.
  • 103
    Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Woude GF, Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802880.
  • 104
    Rosen EM, Laterra J, Joseph A, Jin L, Fuchs A, Way D, Witte M, Weinand M, Goldberg ID: Scatter factor expression and regulation in human glial tumors. Int J Cancer 1996; 67:248255.
  • 105
    Laterra J, Rosen E, Nam M, Ranganathan S, Fielding K, Johnston P: Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochem Biophys Res Commun 1997; 235:743747.
  • 106
    Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R: The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005; 65:93559362.
  • 107
    Walter KA, Hossain MA, Luddy C, Goel N, Reznik TE, Laterra J: Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol 2002; 22:27032715.
  • 108
    Tulasne D, Foveau B: The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 2008; 15:427434.
  • 109
    Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Woude GF, Testa JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001; 98:247252.
  • 110
    Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, Laterra J: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 2000; 60:42774283.
  • 111
    Xu J, Gao M, Fan S, Meng Q, Goldberg ID, Abounader R, Ressom H, Laterra JJ, Rosen EM: Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells. Oncogene 2007; 26:29252938.
  • 112
    Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM: Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005; 24:17491766.
  • 113
    Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, Michalopoulos GK, Zarnegar R: A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 2002; 9:411421.
  • 114
    Moumen A, Ieraci A, Patane S, Sole C, Comella JX, Dono R, Maina F: Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner. Hepatology 2007; 45:12101217.
  • 115
    Rasola A, Anguissola S, Ferrero N, Gramaglia D, Maffe A, Maggiora P, Comoglio PM, Di Renzo MF: Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res 2004; 64:17441750.
  • 116
    Arakaki N, Kazi JA, Kazihara T, Ohnishi T, Daikuhara Y: Hepatocyte growth factor/scatter factor activates the apoptosis signaling pathway by increasing caspase-3 activity in sarcoma 180 cells. Biochem Biophys Res Commun 1998; 245:211215.
  • 117
    Matteucci E, Modora S, Simone M, Desiderio MA: Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells. favouring role of hypoxia-inducible factor-1 deficiency. Oncogene 2003; 22:40624073.
  • 118
    Zhao Y, Difrancesca D, Wang X, Zarnegar R, Michalopoulos GK, Yin XM: Promotion of Fas-mediated apoptosis in Type II cells by high doses of hepatocyte growth factor bypasses the mitochondrial requirement. J Cell Physiol 2007; 213:556563.
  • 119
    Matteucci E, Modora S, Simone M, Desiderio MA: Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: favouring role of hypoxia-inducible factor-1 deficiency. Oncogene 2003; 26:40624073.
  • 120
    Yang HR, Chou HS, Gu X, Wang L, Brown KE, Fung JJ, Lu L, Qian S: Mechanistic insights into immunomodulation by hepatic stellate cells in mice: a critical role of interferon-gamma signaling. Hepatology 2009; 50:19811991.
  • 121
    Benkhoucha M, Santiago-Raber ML, Schneiter G, Chofflon M, Funakoshi H, Nakamura T, Lalive PH: Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. PNAS 2010; 107:64246429.
  • 122
    Hunt JS: Stranger in a strange land. Immunol Rev 2006; 213:3647.
  • 123
    Le Bouteiller P, Tabiasco J, Parinaud J: Soluble HLA-G and embryo implantation: frequently asked questions. Gynecol Obstet Invest 2007; 64:134137.
  • 124
    Pistoia V, Morandi F, Wang X, Ferrone S: Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 2007; 17:469479.
  • 125
    Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N: HLA-G: from biology to clinical benefits. Trends Immunol 2008; 29:125132.
  • 126
    Carosella ED, HoWangYin KY, Favier B, LeMaoult J: HLA-G-dependent suppressor cells: diverse by nature, function, and significance. Hum Reprod 2008; 69:700707.
  • 127
    Baricordi OR, Stignani M, Melchiorri L, Rizzo R: HLA-G and inflammatory diseases. Inflamm Allergy Drug Targets 2008; 7:6774.
  • 128
    Hunt JS, Langat DL: HLA-G: A human pregnancy-related immunomodulator. Curr Opin Pharmacol 2009; 4:462469.
  • 129
    Petroff MG, Sedlmayr P, Azzola D, Hunt JS: Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. J Reprod Immunol 2002; 56:317.
  • 130
    Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A: Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc Natl Acad Sci USA 2008; 105:83578362.
  • 131
    Yu Y, Wang Y, Feng M: Human leukocyte antigen-G1 inhibits natural killer cytotoxicity through blocking the activating signal transduction pathway and formation of activating immunologic synapse. Hum Immunol 2008; 69:1623.